New version of Phentermine in the works: Qnexa

Qnexa is a drug in development by California company Vivus. In a new study published in the Lancet, Qnexa helped individuals not only lose an average of 22 pounds during the year, but also see improvements in blood pressure, cholesterol and blood sugar levels. In this study, Qnexa also helped individuals maintain weight loss for a second year.

Qnexa is a combination of Phentermine and topiramate (a medication more commonly used to treat seizures and migraine headaches).

The FDA previously turned this drug down. However, Vivus will likely re-submit their drug application. Perhaps this study, combined with the recent appointment of Dr. Ed Hendricks (a leading Bariatritian who has published articles in medical journals regarding long-term medical management of obesity) will persuade the FDA to approve this version of Phentermine for long-term use.

Read more information about Qnexa.